BioVersys AG is a privately owned Swiss pharmaceutical company focusing on R&D of small molecules acting on novel bacterial targets." title="" class="btn" data-container="body" data-html="true" data-id="279143" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#b3d4fc" tabindex="0" data-original-title="BioVersys"> 400 6,073
Activities
Entity types
Location
Hochbergerstrasse 60C, 4057 Basel, Switzerland
Basel
Switzerland
Employees
Scale: 11-50
Estimated: 27
Engaged corporates
2Added in Motherbase
1 year, 11 months agoLeadership in overcoming the antibiotic resistance crisis.
BioVersys AG is a privately-owned clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. With the company’s award-winning TRIC technology we can overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria, towards the identification of new treatment options in the antimicrobial and microbiome fields.
By this means, BioVersys addresses the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced research and development programmes address nosocomial infections of Acinetobacter baumannii (BV100, Phase 2), and tuberculosis (BVL-GSK098, Phase 2) in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille. BioVersys is located in the TechPark in the thriving biotech hub of Basel.
Antibiotic resistance, Small molecules, Nosocomial infections, Tuberculosis, AMR, and R&D
Antibiotic-resistant germs are among the most important medical threats of our day and age. ▷ Find out more about our mission to tackle this challenge!
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
![]() J.P. Morgan Bank | J.P. Morgan Bank | Other 11 Jan 2025 | | |
![]() GSK Pharmaceutical, Pharmaceutical Manufacturing | GSK Pharmaceutical, Pharmaceutical Manufacturing | Other 28 May 2024 | |